Nonselective β-blockers plus nitrates in portal hypertension: An open question

Hepatology

Volumn 37, Issue 6, 2003, Pages 1254-1256

  Merkel, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE 5 NITRATE; NADOLOL; NITRATE; PRAZOSIN; PROPRANOLOL; SPIRONOLACTONE;

ASCITES; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; ESOPHAGUS VARICES BLEEDING; HEADACHE; HEART ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; META ANALYSIS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLEROTHERAPY; TREATMENT OUTCOME;

EID: 0038241792     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50274     Document Type: Editorial

References (29)

1. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis:a controlled study. N Engl J Med 1981;305:1371-1374.
2. Pascal JP, Calès P, multicenter study group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-861.
3. Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW, Bosch J, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. HEPATOLOGY 1998;28:868-880.
4. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505.
5. Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D, Franco-Italian Multicenter Study Group. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991;324:1532-1538.
6. Garcia-Pagàn JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to prorpanolol administration in patients with cirrhosis. HEPATOLOGY 1990;11:230-238.
7. Albillos A, Garcia-Pagàn JC, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, Escorsell A, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998;115:116-123.
8. Nevens F, Lijnen P, Van Billoen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. HEPATOLOGY 1996;23:1047-1052.
9. Garcia-Pagàn JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991;114:869-873.
10. Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, Tanno H, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients: long-term hemodynamic and renal effects. HEPATOLOGY 1993;18:477-484.
11. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. HEPATOLOGY 1985;5:97-101.
12. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. HEPATOLOGY 1997;26:34-39.
13. Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. HEPATOLOGY 2000;31:1239-1245.
14. Villanueva C, Balanzò J, Novella MT, Soriano G, Sàinz S, Torras X, Guarner C, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-1629.
15. Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, et al. Endoscopic ligation compared to combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-655.
16. Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs AK. A randomized, controlled study of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013-1019.
17. Lo GH, Chen WC, Chen MH, Hsu PI, Lin CK, Tsai WL, Lai KH. Band ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal rebleeding. Gastroenterology 2002;123:728-734.
18. Groszmann RJ, Garcia-Tsao G. Endoscopic variceal banding vs pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology 2002;123:1388-1391.
19. Garcia-Pagàn JC, Morillas R, Banares R, Albillos A, Villanueva C, Vila C, Genescà J, et al. Propranolol plus placebo vs. propranolol plus isosorbide-5-mononitrate in the prevention of the first variceal bleed. A double blind RCT. HEPATOLOGY 2003;37:1260-1266.
20. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-1681.
21. Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary propohylaxis of variceal bleeding in cirrhosis. HEPATOLOGY 2000;31:324-329.
22. Patti R, D'Amico G, Pasta L, Patti R, Vizzini G, Traina M, Madonna S, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis. A double-blind placebo-controlled randomized trial [Abstract]. J Hepatol 1999;30(suppl 1):55A.
23. Morillas RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, Garcia-Pagàn JC, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. HEPATOLOGY 1994;20:1502-1508.
24. Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and escites formation in patients with cirrhosis. HEPATOLOGY 1995;22:808-813.
25. Albillos A, Lledò JL, Rossi I, Perez-Paramo M, Tabuenca KJ, Banares R, Iborra J, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995;109:1257-1265.
26. Okumura H, Arakami T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
27. Garcia-Pagàn JC, Salmeron J, Feu F, Ginés P, Pizcueta P, Claria J, Arroyo V, et al. Effect of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. HEPATOLOGY 1994;19:1095-1099.
28. Sugano S, Kawafune T, Okajma T, Ishii K, Watanabe M, Takamura N. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998;43:893-897.
29. Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, Landeira G, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleeding in nonascitic cirrhotic patients: a preliminary study. HEPATOLOGY 2003;37:359-365.